Category: 40644-16-4

Cook, James et al. published their research in Bioorganic & Medicinal Chemistry Letters in 2017 |CAS: 40644-16-4

The Article related to azaspiro benzoimidazooxazole bicyclooctane preparation alpha 7 nicotinic acetylcholine receptor, 5-ht(3a) receptor, schizophrenia, spirooxazolines, α7 nicotinic acetylcholine receptor and other aspects.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

On November 15, 2017, Cook, James; Zusi, F. Christopher; Hill, Matthew D.; Fang, Haiquan; Pearce, Bradley; Park, Hyunsoo; Gallagher, Lizbeth; McDonald, Ivar M.; Bristow, Linda; Macor, John E.; Olson, Richard E. published an article.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one The title of the article was Design and synthesis of a novel series of (1’S,2R,4’S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor. And the article contained the following:

We describe an efficient and convergent synthesis of a series of (1’S,2R,4’S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes], such as I (R = H, 5-Cl, 6-Me, etc.) displaying potency for the α7 nicotinic acetylcholine receptor (nAChR) and good selectivity vs. the related 5-HT3A receptor. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

The Article related to azaspiro benzoimidazooxazole bicyclooctane preparation alpha 7 nicotinic acetylcholine receptor, 5-ht(3a) receptor, schizophrenia, spirooxazolines, α7 nicotinic acetylcholine receptor and other aspects.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Cook, James et al. published their research in Bioorganic & Medicinal Chemistry Letters in 2017 |CAS: 40644-16-4

The Article related to azaspiro benzoimidazooxazole bicyclooctane preparation alpha 7 nicotinic acetylcholine receptor, 5-ht(3a) receptor, schizophrenia, spirooxazolines, α7 nicotinic acetylcholine receptor and other aspects.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

On November 15, 2017, Cook, James; Zusi, F. Christopher; Hill, Matthew D.; Fang, Haiquan; Pearce, Bradley; Park, Hyunsoo; Gallagher, Lizbeth; McDonald, Ivar M.; Bristow, Linda; Macor, John E.; Olson, Richard E. published an article.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one The title of the article was Design and synthesis of a novel series of (1’S,2R,4’S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor. And the article contained the following:

We describe an efficient and convergent synthesis of a series of (1’S,2R,4’S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes], such as I (R = H, 5-Cl, 6-Me, etc.) displaying potency for the α7 nicotinic acetylcholine receptor (nAChR) and good selectivity vs. the related 5-HT3A receptor. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

The Article related to azaspiro benzoimidazooxazole bicyclooctane preparation alpha 7 nicotinic acetylcholine receptor, 5-ht(3a) receptor, schizophrenia, spirooxazolines, α7 nicotinic acetylcholine receptor and other aspects.Name: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Buckman, Brad et al. published their patent in 2011 |CAS: 40644-16-4

The Article related to cyclic peptide preparation hepatitis c virus replication inhibitor, ns3 ns4a protease inhibitor hcv infection fibrosis macrocycle preparation, proline peptide peptidomimetic preparation inhibitor hcv replication and other aspects.Recommanded Product: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

On March 31, 2011, Buckman, Brad; Nicholas, John B.; Beigelman, Leonid; Serebryany, Vladimir; Stoycheva, Antitsa Dimitrova; Thrailkill, Timothy; Seiwert, Scott D. published a patent.Recommanded Product: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one The title of the patent was Preparation of macrocyclic peptides, especially proline-containing peptides, as inhibitors of hepatitis C virus replication for treating hepatitis C infection and liver fibrosis. And the patent contained the following:

The invention is related to the preparation of title compounds, e.g., I [R1 = COOBu-t, (un)substituted (hetero)aryl, etc.; R2 = (un)substituted 1-alkylbenzimidazol-2-yloxy, 2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinazolin-4-yloxy, 5-aryl-2H-tetrazol-2-yl, etc.; R3 = OH, NHSO2R3a, NHSO2OR3a; NHSO2NR3bR3c; R3a = (un)substituted alkyl, aryl, cycloalkyl, etc.; R3b, R3c = independently H, (un)substituted alkyl, C6 or C10 aryl, etc.; or NR3bR3c = (un)substituted 3-6 membered heterocyclyl bonded to the parent structure through a N ; with provisos], pharmaceutical acceptable salts and prodrugs and their compositions containing them as inhibitors of hepatitis C virus replication. The invention is also related to methods of treating a hepatitis C virus infection and methods of treating liver fibrosis. Thus, II·HCl was prepared by a multi-step synthesis and displayed an EC50 between 10 and 100 nM and an IC50 < 10 nM in an NS3-NS4 inhibitory activity assay. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Recommanded Product: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

The Article related to cyclic peptide preparation hepatitis c virus replication inhibitor, ns3 ns4a protease inhibitor hcv infection fibrosis macrocycle preparation, proline peptide peptidomimetic preparation inhibitor hcv replication and other aspects.Recommanded Product: 4-Bromo-1H-benzo[d]imidazol-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Bartlett, Mark J. et al. published their patent in 2020 |CAS: 40644-16-4

The Article related to indole preparation ido1 inhibitor antitumor hbv hiv antiviral therapy, azaindole preparation ido1 inhibitor cancer viral infection combination therapy, bicyclic nitrogen heterocycle preparation ido1 inhibitor immunotherapy anticancer antiviral and other aspects.Electric Literature of 40644-16-4

On January 9, 2020, Bartlett, Mark J.; Corkey, Britton Kenneth; Cosman, Jennifer Leigh; Elzein, Elfatih; Li, Xiaofen published a patent.Electric Literature of 40644-16-4 The title of the patent was Preparation of indoles, azaindoles and related bicyclic nitrogen heterocycles useful in treatment of diseases. And the patent contained the following:

The invention relates to preparation of indoles, azaindoles and related bicyclic nitrogen heterocycles of formula (I), or a pharmaceutically acceptable salt thereof, as enzyme indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Compounds I wherein Y1 is O or N; the dotted line is a single bond that is present or absent; X1, X2 and X4 each independently is N or CH; X3 is N or CRa; Ra is H, halo, C1-4 alkyl; X5 is N, C or CRb; X6 is N or CRc; X7 is N or CRd; X8 is N or CRe; Rb-Re and R1 each independently is H, halo, or CN; R2 is C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy; etc., are claimed. The example compound II was prepared via two-step synthesis using 4-bromo-3,3-dimethylindolin-2-one as starting material (procedure given). Compounds I were evaluated for IDO1-inhibitory activity (data given). Compounds I can be useful in mono- amd combination therapy of cancer and viral infections (e.g. HIV and HBV). The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Electric Literature of 40644-16-4

The Article related to indole preparation ido1 inhibitor antitumor hbv hiv antiviral therapy, azaindole preparation ido1 inhibitor cancer viral infection combination therapy, bicyclic nitrogen heterocycle preparation ido1 inhibitor immunotherapy anticancer antiviral and other aspects.Electric Literature of 40644-16-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

9/27/2021 News Extended knowledge of 40644-16-4

These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route 4-Bromo-1H-benzo[d]imidazol-2(3H)-one, its application will become more common.

Synthetic Route of 40644-16-4,Some common heterocyclic compound, 40644-16-4, name is 4-Bromo-1H-benzo[d]imidazol-2(3H)-one, molecular formula is C7H5BrN2O, traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route.

Step 3: 4-(4,4,5,5-Tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 ,3-dihydro-benzoimidazol- 2-one To a solution of 4-bromo-1 ,3-dihydro-benzoimidazol-2-one (701 mg, 3.29 mmol) in dimethyl sulfoxide (2 ml_) was added potassium acetate (803 g, 10.9 mmol), 1,1′-bis(diphenyl phosphino) ferrocene palladium chloride (PdCI2 (dppf)) (134 mg, 0.16 mmol) and bis(pinacolato) diboron (1.67 g, 6.58 mmol). The mixture was degassed and heated in a microwave oven for 30 minutes at 150 0C. The solvent was filtered through a pad of celite, water (60 ml_) was added and the product was extracted with EtOAc (3 x, 30 ml_). The combined organic extracts were dried over Na2SO4 (sodium sulfate), and the solvent removed to provide crude 4-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-1 ,3-dihydro-benzoimidazol-2-one which was used without further purification.

These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route 4-Bromo-1H-benzo[d]imidazol-2(3H)-one, its application will become more common.

Reference:
Patent; WYETH; WO2009/111260; (2009); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Application of 40644-16-4

The synthetic route of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one has been constantly updated, and we look forward to future research findings.

These common heterocyclic compound, 40644-16-4, name is 4-Bromo-1H-benzo[d]imidazol-2(3H)-one, its traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route. COA of Formula: C7H5BrN2O

Step 3: To a solution of 4-bromo-1 ,3-dihydro-benzoimidazol-2-one (701 mg, 3.29 mmol) in DMSO (2 ml.) was added potassium acetate (803 g, 10.9 mmol), 1 ,1 ‘-bis(diphenyl phosphino)ferrocene palladium chloride (134 mg, 0.16 mmol) and bis(pinacolato)diboron (1.67 g, 6.58 mmol), and the reaction was degassed and heated in a microwave reactor for 30 minutes at 150 C. The reaction mixture was then filtered through a pad of Celite, water (60 ml.) was added, and the mixture was extracted with ethyl acetate (3 x 30 ml_). The combined organic extracts were dried over sodium sulfate, filtered, and then concentrated in- vacuo to give 4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 ,3-dihydro-benzoimidazol-2- one, which was used in the next step without further purification.

The synthetic route of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one has been constantly updated, and we look forward to future research findings.

Reference:
Patent; WYETH; WO2009/108838; (2009); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Extended knowledge of 40644-16-4

These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route 4-Bromo-1H-benzo[d]imidazol-2(3H)-one, its application will become more common.

Reference of 40644-16-4,Some common heterocyclic compound, 40644-16-4, name is 4-Bromo-1H-benzo[d]imidazol-2(3H)-one, molecular formula is C7H5BrN2O, traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route.

Step 3: 4-(4,4,5,5-Tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 ,3-dihydro-benzoimidazol- 2-one To a solution of 4-bromo-1 ,3-dihydro-benzoimidazol-2-one (701 mg, 3.29 mmol) in dimethyl sulfoxide (2 ml_) was added potassium acetate (803 g, 10.9 mmol), 1,1′-bis(diphenyl phosphino) ferrocene palladium chloride (PdCI2 (dppf)) (134 mg, 0.16 mmol) and bis(pinacolato) diboron (1.67 g, 6.58 mmol). The mixture was degassed and heated in a microwave oven for 30 minutes at 150 0C. The solvent was filtered through a pad of celite, water (60 ml_) was added and the product was extracted with EtOAc (3 x, 30 ml_). The combined organic extracts were dried over Na2SO4 (sodium sulfate), and the solvent removed to provide crude 4-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-1 ,3-dihydro-benzoimidazol-2-one which was used without further purification.

These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route 4-Bromo-1H-benzo[d]imidazol-2(3H)-one, its application will become more common.

Reference:
Patent; WYETH; WO2009/111260; (2009); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem